Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Inclusion Criteria:

1. Be 18 to 75 years old at the time of signing the informed consent.

2. Diagnosed with type 2 diabetes ≥ 180 days before screening.

3. HbA1c value at screening of ≥ 7.0% (53 mmol/mol) and ≤ 10% (86 mmol/mol).

4. On a stable maintenance dose of an injectable GLP-1 RA.

5. At Screening, have a BMI ≥ 27 kg/m2

Exclusion Criteria:

1. Has received treatment with prescription or non-prescription medication for weightloss within the last 3 months prior to screening (other than a GLP-1 RA).

2. Self-reported weight change of > 5 % in the 3 months prior to screening.

3. Diabetes mellitus that is not clearly type 2 diabetes.

4. Use of insulin therapy for T2DM

5. Previous or planned (within study period) bariatric surgery or fitting of a weightloss device (eg, gastric balloon or duodenal barrier)

6. Significant hepatobiliary disease (except for non-alcoholic steatohepatitis ornonalcoholic fatty liver disease without portal hypertension or cirrhosis)

7. Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73m2 at screening